{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:39:31Z","timestamp":1795027171751,"version":"4.10.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002447","name":"Catholic University of Daegu","doi-asserted-by":"publisher","award":["2023"],"award-info":[{"award-number":["2023"]}],"id":[{"id":"10.13039\/501100002447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002447","name":"Catholic University of Daegu","doi-asserted-by":"publisher","award":["2023"],"award-info":[{"award-number":["2023"]}],"id":[{"id":"10.13039\/501100002447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-00166945"],"award-info":[{"award-number":["RS-2022-00166945"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-87421-w","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:54:21Z","timestamp":1739642061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the Food and Drug Administration adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Nai","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hoon","family":"Ok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-jin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"87421_CR1","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S1474-4422(18)30322-3","volume":"17","author":"GBDH Collaborators","year":"2018","unstructured":"Collaborators, G. B. D. H. Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 17, 954\u2013976. https:\/\/doi.org\/10.1016\/S1474-4422(18)30322-3 (2018).","journal-title":"Lancet Neurol."},{"key":"87421_CR2","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International classification of Headache disorders, 3rd edition. Cephalalgia 38 1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202 (2018).","DOI":"10.1177\/0333102417738202"},{"key":"87421_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11916-010-0157-z","volume":"15","author":"AN Manack","year":"2011","unstructured":"Manack, A. N., Buse, D. C. & Lipton, R. B. Chronic migraine: epidemiology and disease burden. Curr. Pain Headache Rep. 15, 70\u201378. https:\/\/doi.org\/10.1007\/s11916-010-0157-z (2011).","journal-title":"Curr. Pain Headache Rep."},{"issue":"Suppl 2","key":"87421_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s100720300052","volume":"24","author":"D D\u2019Amico","year":"2003","unstructured":"D\u2019Amico, D. et al. Quality of life and disability in primary chronic daily headaches. Neurol. Sci. 24 (Suppl 2), 97\u2013100. https:\/\/doi.org\/10.1007\/s100720300052 (2003).","journal-title":"Neurol. Sci."},{"key":"87421_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal, M. E., Serrano, D., Reed, M. & Lipton, R. B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71, 559\u2013566. https:\/\/doi.org\/10.1212\/01.wnl.0000323925.29520.e7 (2008).","journal-title":"Neurology"},{"key":"87421_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villalon","year":"2009","unstructured":"Villalon, C. M. & Olesen, J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther. 124, 309\u2013323. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.09.003 (2009).","journal-title":"Pharmacol. Ther."},{"key":"87421_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11916-019-0768-y","volume":"23","author":"I Urits","year":"2019","unstructured":"Urits, I. et al. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr. Pain Headache Rep. 23, 29. https:\/\/doi.org\/10.1007\/s11916-019-0768-y (2019).","journal-title":"Curr. Pain Headache Rep."},{"key":"87421_CR8","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson, L., Haanes, K. A., Warfvinge, K. & Krause, D. N. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"87421_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejphar.2008.02.091","volume":"585","author":"A Maassenvandenbrink","year":"2008","unstructured":"Maassenvandenbrink, A. & Chan, K. Y. Neurovascular pharmacology of migraine. Eur. J. Pharmacol. 585, 313\u2013319. https:\/\/doi.org\/10.1016\/j.ejphar.2008.02.091 (2008).","journal-title":"Eur. J. Pharmacol."},{"key":"87421_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s10194-017-0807-1","volume":"18","author":"M Deen","year":"2017","unstructured":"Deen, M. et al. Blocking CGRP in migraine patients - a review of pros and cons. J. Headache Pain. 18, 96. https:\/\/doi.org\/10.1186\/s10194-017-0807-1 (2017).","journal-title":"J. Headache Pain"},{"key":"87421_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein, S. D. et al. Fremanezumab for the Preventive treatment of chronic migraine. N Engl. J. Med. 377, 2113\u20132122. https:\/\/doi.org\/10.1056\/NEJMoa1709038 (2017).","journal-title":"N Engl. J. Med."},{"key":"87421_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer, V. L. et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 75, 1080\u20131088. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1212 (2018).","journal-title":"JAMA Neurol."},{"key":"87421_CR13","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick, D. W. et al. Ubrogepant for the treatment of migraine. N Engl. J. Med. 381, 2230\u20132241. https:\/\/doi.org\/10.1056\/NEJMoa1813049 (2019).","journal-title":"N Engl. J. Med."},{"key":"87421_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton, R. B. et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl. J. Med. 381, 142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090 (2019).","journal-title":"N Engl. J. Med."},{"key":"87421_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani, J. et al. Atogepant for the preventive treatment of migraine. N Engl. J. Med. 385, 695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908 (2021).","journal-title":"N Engl. J. Med."},{"key":"87421_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/head.14245","volume":"62","author":"RC Burch","year":"2022","unstructured":"Burch, R. C., Ailani, J. & Robbins, M. S. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 62, 111\u2013112. https:\/\/doi.org\/10.1111\/head.14245 (2022).","journal-title":"Headache"},{"key":"87421_CR17","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/0140-6736(90)93307-b","volume":"336","author":"CB Bunker","year":"1990","unstructured":"Bunker, C. B., Terenghi, G., Springall, D. R., Polak, J. M. & Dowd, P. M. Deficiency of calcitonin gene-related peptide in Raynaud\u2019s phenomenon. Lancet 336, 1530\u20131533. https:\/\/doi.org\/10.1016\/0140-6736(90)93307-b (1990).","journal-title":"Lancet"},{"key":"87421_CR18","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1365-2133.1996.tb16221.x","volume":"134","author":"CB Bunker","year":"1996","unstructured":"Bunker, C. B. et al. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud\u2019s phenomenon. Br. J. Dermatol. 134, 399\u2013406 (1996).","journal-title":"Br. J. Dermatol."},{"key":"87421_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.1984.00350160096017","volume":"144","author":"I Zahavi","year":"1984","unstructured":"Zahavi, I., Chagnac, A., Hering, R., Davidovich, S. & Kuritzky, A. Prevalence of Raynaud\u2019s phenomenon in patients with migraine. Arch. Intern. Med. 144, 742\u2013744 (1984).","journal-title":"Arch. Intern. Med."},{"key":"87421_CR20","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1136\/ard.59.3.206","volume":"59","author":"PV Voulgari","year":"2000","unstructured":"Voulgari, P. V. et al. Prevalence of Raynaud\u2019s phenomenon in a healthy Greek population. Ann. Rheum. Dis. 59, 206\u2013210. https:\/\/doi.org\/10.1136\/ard.59.3.206 (2000).","journal-title":"Ann. Rheum. Dis."},{"key":"87421_CR21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1111\/head.13596","volume":"59","author":"RW Evans","year":"2019","unstructured":"Evans, R. W. Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache 59, 1360\u20131364. https:\/\/doi.org\/10.1111\/head.13596 (2019).","journal-title":"Headache"},{"key":"87421_CR22","doi-asserted-by":"publisher","first-page":"e217934","DOI":"10.1001\/jamanetworkopen.2021.7934","volume":"4","author":"ID Breen","year":"2021","unstructured":"Breen, I. D. et al. Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw. Open. 4, e217934. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.7934 (2021).","journal-title":"JAMA Netw. Open."},{"key":"87421_CR23","doi-asserted-by":"publisher","first-page":"e04625","DOI":"10.1002\/ccr3.4625","volume":"9","author":"AH Manickam","year":"2021","unstructured":"Manickam, A. H., Buture, A., Tomkins, E. & Ruttledge, M. Raynaud\u2019s phenomenon secondary to erenumab in a patient with chronic migraine. Clin. Case Rep. 9, e04625. https:\/\/doi.org\/10.1002\/ccr3.4625 (2021).","journal-title":"Clin. Case Rep."},{"key":"87421_CR24","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"87421_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s10194-022-01424-w","volume":"23","author":"AO Gerard","year":"2022","unstructured":"Gerard, A. O. et al. Calcitonin gene-related peptide-targeting drugs and Raynaud\u2019s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J. Headache Pain. 23, 53. https:\/\/doi.org\/10.1186\/s10194-022-01424-w (2022).","journal-title":"J. Headache Pain"},{"key":"87421_CR26","doi-asserted-by":"publisher","first-page":"1257282","DOI":"10.3389\/fphar.2023.1257282","volume":"14","author":"W Sun","year":"2023","unstructured":"Sun, W. et al. Adverse event reporting of four anti-calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. Front. Pharmacol. 14, 1257282. https:\/\/doi.org\/10.3389\/fphar.2023.1257282 (2023).","journal-title":"Front. Pharmacol."},{"key":"87421_CR27","doi-asserted-by":"publisher","unstructured":"Liang, Q. et al. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases. Front. Pharmacol. 15, 1431562 https:\/\/doi.org\/10.3389\/fphar.2024.1431562 (2024).","DOI":"10.3389\/fphar.2024.1431562"},{"key":"87421_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/head.14417","volume":"62","author":"K Bedrin","year":"2022","unstructured":"Bedrin, K., Ailani, J. & Dougherty, C. Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide receptor antagonists case report. Headache 62, 1419\u20131423. https:\/\/doi.org\/10.1111\/head.14417 (2022).","journal-title":"Headache"},{"key":"87421_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10194-005-0153-6","volume":"6","author":"P Geppetti","year":"2005","unstructured":"Geppetti, P. et al. CGRP and migraine: neurogenic inflammation revisited. J. Headache Pain. 6, 61\u201370. https:\/\/doi.org\/10.1007\/s10194-005-0153-6 (2005).","journal-title":"J. Headache Pain"},{"key":"87421_CR30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1468-2982.2003.00719.x","volume":"24","author":"L Edvinsson","year":"2004","unstructured":"Edvinsson, L. Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 24, 611\u2013622. https:\/\/doi.org\/10.1111\/j.1468-2982.2003.00719.x (2004).","journal-title":"Cephalalgia"},{"key":"87421_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen, L. H. et al. CGRP may play a causative role in migraine. Cephalalgia 22, 54\u201361. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00310.x (2002).","journal-title":"Cephalalgia"},{"key":"87421_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/path.1711640310","volume":"164","author":"G Terenghi","year":"1991","unstructured":"Terenghi, G. et al. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud\u2019s phenomenon and systemic sclerosis. J. Pathol. 164, 245\u2013252. https:\/\/doi.org\/10.1002\/path.1711640310 (1991).","journal-title":"J. Pathol."},{"key":"87421_CR33","doi-asserted-by":"publisher","first-page":"18128","DOI":"10.1038\/s41598-024-68846-1","volume":"14","author":"E Tekavec","year":"2024","unstructured":"Tekavec, E. et al. Serum levels of biomarkers related to severity staging of Raynaud\u2019s phenomenon, neurosensory manifestations, and vibration exposure in patients with hand-arm vibration injury. Sci. Rep. 14, 18128. https:\/\/doi.org\/10.1038\/s41598-024-68846-1 (2024).","journal-title":"Sci. Rep."},{"key":"87421_CR34","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.26658","volume":"94","author":"G Garate","year":"2023","unstructured":"Garate, G. et al. Serum alpha and Beta-CGRP levels in chronic migraine patients before and after monoclonal antibodies against CGRP or its receptor. Ann. Neurol. 94, 285\u2013294. https:\/\/doi.org\/10.1002\/ana.26658 (2023).","journal-title":"Ann. Neurol."},{"key":"87421_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13421","author":"A van der Gaag","year":"2024","unstructured":"van der Gaag, A., Cohen, S. P., Stojanovic, M. P., Huygen, F. & Kallewaard, J. W. 12. Vascular pain ischemic pain in the extremities and Raynaud\u2019s syndrome. Pain Pract. https:\/\/doi.org\/10.1111\/papr.13421 (2024).","journal-title":"Pain Pract."},{"key":"87421_CR36","doi-asserted-by":"publisher","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","volume":"5","author":"R Garner","year":"2015","unstructured":"Garner, R., Kumari, R., Lanyon, P., Doherty, M. & Zhang, W. Prevalence, risk factors and associations of primary Raynaud\u2019s phenomenon: systematic review and meta-analysis of observational studies. BMJ Open. 5, e006389. https:\/\/doi.org\/10.1136\/bmjopen-2014-006389 (2015).","journal-title":"BMJ Open."},{"key":"87421_CR37","first-page":"123","volume":"113","author":"KK Temprano","year":"2016","unstructured":"Temprano, K. K. A review of Raynaud\u2019s disease. Mo Med. 113, 123\u2013126 (2016).","journal-title":"Mo Med."},{"key":"87421_CR38","doi-asserted-by":"publisher","first-page":"CD006687","DOI":"10.1002\/14651858.CD006687.pub4","volume":"5","author":"KY Su","year":"2021","unstructured":"Su, K. Y. et al. Vasodilators for primary Raynaud\u2019s phenomenon. Cochrane Database Syst. Rev. 5, CD006687. https:\/\/doi.org\/10.1002\/14651858.CD006687.pub4 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"87421_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jaad.2022.05.067","volume":"90","author":"P Curtiss","year":"2024","unstructured":"Curtiss, P., Svigos, K., Schwager, Z., Lo Sicco, K. & Franks Jr, A. G. Part II: the treatment of primary and secondary Raynaud\u2019s phenomenon. J. Am. Acad. Dermatol. 90, 237\u2013248. https:\/\/doi.org\/10.1016\/j.jaad.2022.05.067 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"87421_CR40","doi-asserted-by":"publisher","first-page":"e21681","DOI":"10.7759\/cureus.21681","volume":"14","author":"I Nawaz","year":"2022","unstructured":"Nawaz, I., Nawaz, Y., Nawaz, E., Manan, M. R. & Mahmood, A. Raynaud\u2019s phenomenon: reviewing the pathophysiology and management strategies. Cureus 14, e21681. https:\/\/doi.org\/10.7759\/cureus.21681 (2022).","journal-title":"Cureus"},{"key":"87421_CR41","doi-asserted-by":"publisher","unstructured":"Cutroneo, P. M. et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul. 3 https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057 (2024).","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"87421_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi, E., Fusaroli, M., Ardizzoni, A., Poluzzi, E. & De Ponti, F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res. Treat. 186, 219\u2013227. https:\/\/doi.org\/10.1007\/s10549-020-06001-w (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"87421_CR43","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente, A., Gregoire, F., Fourrier-Reglat, A., Haramburu, F. & Moore, N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 30, 891\u2013898. https:\/\/doi.org\/10.2165\/00002018-200730100-00007 (2007).","journal-title":"Drug Saf."},{"key":"87421_CR44","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi, E. et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr. Metab. Cardiovasc. Dis. 28, 533\u2013542. https:\/\/doi.org\/10.1016\/j.numecd.2018.02.014 (2018).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"87421_CR45","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman, K. B., Demakas, A. R., Dimbil, M., Tatonetti, N. P. & Erdman, C. B. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS). Drug Saf. 37, 971\u2013980. https:\/\/doi.org\/10.1007\/s40264-014-0225-0 (2014).","journal-title":"Drug Saf."},{"key":"87421_CR46","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40264-015-0341-5","volume":"38","author":"AC Pacurariu","year":"2015","unstructured":"Pacurariu, A. C. et al. Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf. 38, 1201\u20131210. https:\/\/doi.org\/10.1007\/s40264-015-0341-5 (2015).","journal-title":"Drug Saf."},{"key":"87421_CR47","doi-asserted-by":"publisher","first-page":"106811","DOI":"10.1016\/j.phrs.2023.106811","volume":"193","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. A novel approach for pharmacological substantiation of safety signals using plasma concentrations of medication and administrative\/healthcare databases: a case study using Danish registries for an FDA warning on lamotrigine. Pharmacol. Res. 193, 106811. https:\/\/doi.org\/10.1016\/j.phrs.2023.106811 (2023).","journal-title":"Pharmacol. Res."},{"key":"87421_CR48","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fphar.2018.00594","volume":"9","author":"VK Patadia","year":"2018","unstructured":"Patadia, V. K. et al. Can electronic health records databases complement spontaneous reporting system databases? A historical-reconstruction of the association of rofecoxib and acute myocardial infarction. Front. Pharmacol. 9, 594. https:\/\/doi.org\/10.3389\/fphar.2018.00594 (2018).","journal-title":"Front. Pharmacol."},{"key":"87421_CR49","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/2168479013514236","volume":"48","author":"L Huang","year":"2014","unstructured":"Huang, L., Guo, T., Zalkikar, J. N. & Tiwari, R. C. A review of statistical methods for safety surveillance. Ther. Innov. Regul. Sci. 48, 98\u2013108. https:\/\/doi.org\/10.1177\/2168479013514236 (2014).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"87421_CR50","unstructured":"European Medicines Agency. Screening for adverse reactions in EudraVigilance. https:\/\/www.ema.europa.eu\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf"},{"key":"87421_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"87421_CR52","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The REporting of a disproportionality analysis for DrUg Safety Signal Detection using individual Case Safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 47, 585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7 (2024).","journal-title":"Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87421-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87421-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:54:24Z","timestamp":1739642064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87421-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87421"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87421-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"1 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5675"}}